Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brivanib alaninate + capecitabine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Brivanib alaninate + capecitabine is a **combination therapy** comprising two agents: brivanib alaninate, an orally bioavailable prodrug of brivanib, and capecitabine, an oral prodrug of 5-fluorouracil. **Brivanib alaninate** is a small molecule that acts as a potent selective dual inhibitor of **vascular endothelial growth factor receptor (VEGFR)** and **fibroblast growth factor receptor (FGFR)** tyrosine kinases, blocking autocrine and paracrine signaling pathways that drive tumor angiogenesis and growth[4][6][2]. **Capecitabine** is metabolized to 5-fluorouracil in tumor tissue, acting as an antimetabolite to inhibit DNA synthesis and cell proliferation. This combination is evaluated for enhanced **anti-tumor efficacy** by combining targeted inhibition of cancer cell angiogenesis (brivanib) with cytotoxic chemotherapy (capecitabine), especially in gastrointestinal and hepatic cancers.
- Other names
- brivanib alaninate + capecitabine
02
Targets
FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on brivanib alaninate + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brivanib alaninate + capecitabine.